№ files_lp_4_process_2_43849
Detailed tabular data summarizing clinical trials, dosing regimens, patient demographics, and observed resistance mutations in Gram-negative bacteria.
Year: 2009–2017
Region / City: Shenzhen, Hangzhou, California, London, Overland Park, Michigan
Theme: Antimicrobial resistance, Clinical pharmacology
Document type: Supplementary data / Clinical study summary
Institution: Shenzhen Institute of Respiratory Diseases; State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Zhejiang University; University of Southern California; AstraZeneca; Pfizer; Forest Laboratories
Authors: Tingting Xu, Yuqi Guo, Yang Ji, Baohong Wang, Kai Zhou
Target audience: Researchers in microbiology and pharmacology
Study population: Adults and children (3 months–90 years), healthy volunteers and patients with infections
Clinical conditions: Cystic fibrosis, complicated urinary tract infections, intra-abdominal infections, neutropenic febrile conditions, systemic infections, ICU patients
Trial phases: I–IV
Interventions: Ceftazidime–avibactam alone or in combination with other antibiotics
Completion dates: 2009–2017
Locations of resistance studies: UK, in vitro assays
Organisms studied: K. pneumoniae
Resistance mechanisms: KPC-3 mutants with amino acid substitutions and insertions
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.